

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended April 1, 2018 net sales growth/(decline)

Product line	U.S. as reported	Int'l constant currency	Int'l as reported	Global constant currency	Global as reported
Lower extremities	2%	2%	12%	2%	4%
Upper extremities	21%	18%	32%	20%	24%
Biologics	(3%)	(2%)	2%	(2%)	(2%)
Sports med & other	2%	(17%)	(6%)	(10%)	(3%)
Total net sales	10%	8%	19%	9%	12%

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)

	Three months ended	
	April 1, 2018	March 26, 2017
Net loss from continuing operations, as reported	\$ (19,907)	\$ (36,707)
Net loss from continuing operations per share, as reported	\$ (0.19)	\$ (0.35)
Reconciling items:		
Non-cash interest expense on convertible notes ¹	12,012	10,999
Derivatives mark-to-market adjustments ²	1,694	365
Transaction and transition costs	910	2,972
Foreign currency translation expense ²	763	—
CVR mark-to-market adjustments ²	(3,924)	6,160
Contingent consideration fair value adjustment ²	414	—
Tax effect of reconciling items ³	(210)	(18)
Non-GAAP net loss from continuing operations, as adjusted	\$ (8,248)	\$ (16,229)
Add back amortization of intangible assets	7,141	7,397
Adjusted non-GAAP earnings	\$ (1,107)	\$ (8,832)
Weighted-average basic shares outstanding	105,904	103,663
Adjusted non-GAAP earnings per share	\$ (0.01)	\$ (0.09)

¹ Impacting interest expense, net

² Impacting other (income) expense, net

³ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	April 1, 2018	March 26, 2017
Net loss from continuing operations	\$ (19,907)	\$ (36,707)
Interest expense, net	19,812	18,195
Provision from income taxes	205	939
Depreciation	14,499	13,446
Amortization	7,141	7,397
Non-GAAP EBITDA	\$ 21,750	\$ 3,270
Reconciling items impacting EBITDA:		
Non-cash share-based compensation expense	5,018	3,954
Other (income) expense, net	(1,000)	7,975
Transaction and transition costs	910	2,972
Non-GAAP adjusted EBITDA	\$ 26,678	\$ 18,171
Net sales from continuing operations	198,537	177,191
Non-GAAP adjusted EBITDA margin	13.4%	10.3%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended	
	April 1, 2018	March 26, 2017
Gross profit from continuing operations, as reported	\$ 157,398	\$ 140,065
Gross margins from continuing operations, as reported	79.3 %	79.0 %
Reconciling items impacting gross profit:		
Transaction and transition costs	910	685
Non-GAAP gross profit from continuing operations, as adjusted	\$ 158,308	\$ 140,750
Net sales from continuing operations	198,537	177,191
Non-GAAP adjusted gross margins from continuing operations	79.7%	79.4%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended	
	April 1, 2018	March 26, 2017
Net sales	\$ 198,537	\$ 177,191
Selling, general and administrative expense, as reported	\$ 137,248	\$ 129,834
Selling, general and administrative expense as a percentages of net sales, as reported	69.1 %	73.3 %
Reconciling items impacting selling, general and administrative expense:		
Transaction and transition costs - selling, general and administrative	—	2,287
Selling, general and administrative expense, as adjusted	\$ 137,248	\$ 127,547
Selling, general and administrative expense as a percentage of net sales, as adjusted	69.1%	72.0%